Dissecting MedTech M&A deals

By Shreya Gupta (Toronto) on November 20, 2018 Posted in M&A, Pharmaceuticals and life sciences

As we previously reported, this year has seen a surge in healthcare-related M&A. Many of these transactions are in the medical technology industry, or MedTech. While the industry’s healthy profit margins and opportunities for growth have driven a flurry of activity, the potential for large rewards from MedTech acquisitions also comes with unique obstacles: Regulatory compliance: … Continue reading

Assessing corruption risks in M&A transactions

By nrfdigitalteam on October 22, 2015 Posted in Corporate finance, Governance and directors' liability

In a previous post, we discussed the importance of considering anti-corruption and bribery risks when engaging in international transactions. In connection with the OECD Convention on Combatting Bribery of Foreign Public Officials in International Business Transactions, Canada, the US and the UK, as well as an increasing number of legislatures around the world have implemented … Continue reading

Hidden dangers in M&A: bribery and corruption

By Troy Ungerman (Toronto) on July 29, 2014 Posted in Antitrust, competition and regulatory, Corporate finance

Embarking on an international M&A transaction can be an exhilarating time for any company, although there are a host of business and legal issues involved in choosing an appropriate target. One issue that often gets overlooked is the target company’s anti-corruption and bribery practices. As Canadian companies continue to grab up international market space, they … Continue reading